CTLA4 and familial pancreatic carcinoma: However, based on the early clinical trials, checkpoint inhibitors, such as anti-CTLA-4, anti-PD-1 or anti-PD-L1, are ineffective when used as monotherapy in the treatment of pancreatic cancer [76].